The study focuses on Follicular Lymphoma, a slow‑growing cancer that starts in the lymph nodes and can spread to other parts of the blood‑forming system. The experimental treatment combines a new drug called MK-1045 with rituximab, a medication that helps the immune system recognize and destroy cancer cells. Both medicines are given by intravenous infusion, which means they are delivered directly into a vein through a short needle.
The purpose is to determine whether the combination is safe and works better than the usual chemotherapy plus rituximab. Safety is evaluated by recording any adverse events (unwanted medical problems) and any dose‑limiting toxicity (a side effect that prevents increasing the dose). Effectiveness is judged by the rate of complete response, meaning all detectable cancer disappears, and by PFS, the length of time a person lives without the disease getting worse.
Participants receive the study medicines in repeated cycles that last a few weeks, with regular clinic visits for blood tests, imaging scans, and overall health checks. After the treatment period, they are followed for several years to watch for any return of the cancer and to continue safety monitoring. All data are collected confidentially and in accordance with standard clinical‑trial procedures.
France 
Spain 
